Company intelligence / Profile preview

Cincera Therapeutics

Melbourne, Victoria, Australiacinceratx.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Cincera Therapeutics develops potent, orally available small molecule inhibitors targeting a key enzyme in lipid metabolism. Their approach reduces fibrosis and inflammation at lower doses than current therapies by modulating the quality rather than the quantity of bioactive lipids. Preclinical data show strong anti-inflammatory/anti-fibrotic effects with potential for single-agent or combination use in metabolic diseases such as NASH, CKD, and others.

Therapeutic areas: Metabolic DisordersOncologyImmunologyGastroenterologyNephrology
Modalities: Small molecules (orally available inhibitors)
Industry: Biotech

Drug pipeline

3 assets

Des-1 inhibitor

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cincera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cincera Therapeutics.

Explore the full profile